For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What is the projected market size of the tysabri (natalizumab) industry, and what is its expected CAGR?
The tysabri (natalizumab) market size has grown strongly in recent years. It will grow from $2,460 million in 2024 to $2,660 million in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to efficacy in treating multiple sclerosis, its ability to target specific immune cells, its approval for multiple autoimmune disorders, strong clinical trial data, growing demand for effective disease-modifying therapies, and increasing patient awareness of treatment options.
The tysabri (natalizumab) market size is expected to see strong growth in the next few years. It will grow to $3,600 million in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing prevalence of autoimmune disorders, growing demand for effective treatments in multiple sclerosis and Crohn’s disease, advancements in biosimilars, expanding patient access in underserved regions, and ongoing clinical research supporting its use in other autoimmune conditions. Major trends in the forecast period include rising adoption of biosimilars, the expansion of their therapeutic applications beyond multiple sclerosis, increased focus on personalized medicine, growing partnerships for global distribution, enhanced patient access through affordability initiatives, and continued advancements in immune-modulating therapies.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19942&type=smp
What external factors are influencing the tysabri (natalizumab) market’s growth momentum?
The rise in the prevalence of autoimmune disorders is expected to propel the growth of the tysabri (natalizumab) market going forward. Autoimmune disorders are conditions where the immune system mistakenly attacks the body’s own cells, tissues, or organs, causing inflammation and damage, leading to chronic conditions such as rheumatoid arthritis or multiple sclerosis, with causes involving a mix of genetic and environmental factors. The rise in the prevalence of autoimmune disorders is due to factors such as genetic predisposition, environmental triggers, and improved awareness and diagnosis, leading to more cases being identified. Tysabri is effective for autoimmune disorders as it targets specific immune cells, preventing them from causing inflammation and damage, which helps treat conditions such as multiple sclerosis and Crohn’s disease. For instance, in March 2024, according to the National Health Council, a US-based non-profit organization, autoimmune diseases affected around 50 million Americans and is rising rapidly, with cases increasing by 3-12% annually. Globally, multiple sclerosis cases grew by 30% in 2022 compared to the previous decade. Therefore, the rise in the prevalence of autoimmune disorders is driving growth in the tysabri (natalizumab) market.
Rise Of Personalized Medicine Fueling Growth In The Tysabri (natalizumab) Market
Rising personalized medicine is expected to propel the growth of the tysabri (natalizumab) market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient, such as their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The rising personalized medicine is due to advancements in genomic technologies, increased understanding of molecular biology, growing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Tysabri (natalizumab) exemplifies the principles of personalized medicine by offering a targeted treatment approach for relapsing forms of multiple sclerosis, tailored to patients who exhibit specific disease activity and risk profiles, thereby maximizing therapeutic efficacy while minimizing potential adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Moreover, it includes seven drugs tailored for cancer treatment and three targeting different diseases and conditions. Therefore, rising personalized medicine drives the tysabri (natalizumab) market.
What are the major market segments driving the growth of the tysabri (natalizumab) industry?
The tysabri (natalizumab) market covered in this report is segmented –
1) By Clinical Indication: Multiple Sclerosis; Crohn’s Disease
2) By Patient Setting: Inpatient; Outpatient
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/tysabri-natalizumab-global-market-report
Which trends are expected to dominate the tysabri (natalizumab) market landscape in the coming years?
The key trend in the tysabri (natalizumab) market is focusing on expanding treatment options with alternative solutions, such as biosimilars, to provide patients with more effective therapies that improve quality of life and disease management. Biosimilars to Tysabri offer a cost-effective alternative for treating highly active relapsing-remitting multiple sclerosis, increasing access to essential treatment, especially in underserved regions. For instance, in January 2024, Sandoz Group AG, a Switzerland-based pharmaceutical company, launched Tyruko (natalizumab), the first and only biosimilar to Tysabri, for the treatment of adults with highly active relapsing-remitting multiple sclerosis (RRMS). This launch strengthens Sandoz’s biosimilar portfolio and aims to improve access to effective and affordable treatments for people living with multiple sclerosis.
Who are the key market players contributing to the growth of the tysabri (natalizumab) industry?
Major companies operating in the tysabri (natalizumab) market include Biogen Idec Inc., Sandoz International GmbH, Polpharma Biologics
Which regions are leading the growth of the tysabri (natalizumab) market globally?
North America was the largest region in the tysabri (natalizumab) market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tysabri (natalizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Tysabri (natalizumab) Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19942
Need Customized Data On Tysabri (natalizumab) Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=19942&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
